Zilucoplan: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), CHUIKYO (Japan) and CIPM (Spain), among others, recommended or restricted zilucoplan, while DMC (Denmark) and HAS (France) did not recommend it.
The record spans 3.5 years, opening at AWMSG (Wales) on 17 Mar 2023 and running to 3 Sep 2026.
PBAC (Australia) changed its position: not recommended in 2024, recommended by 2025, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 12 of 12 records date from 2023 or later.
3 distinct indication wordings are recorded for zilucoplan by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 12 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess zilucoplan, on 17 Mar 2023; HIRA (South Korea) did not open a file until 3 Sep 2026 — a wide spread of 3.5 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 12 dated records fall in 2024 alone.
PBAC (Australia) is the only agency to have returned to zilucoplan, recording 2 separate entries.
11 of the 18 agencies in this archive hold a record for zilucoplan.
The full ledger for zilucoplan reads 5 recommended, 3 not recommended, 2 restricted and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 10 Aug 2026 | As an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti‑acetylcholine receptor (AChR) antibody positive. | accepted (restricted) | source |
| AOTMIT (Poland) | 28 May 2026 | programu lekowego B.157 „Leczenie chorych z uogólnioną postacią miastenii (ICD-10: G70.0) | recommended conditionally | source |
| PBAC (Australia) | 2025 | Generalised myasthenia gravis (gMG) | Recommended | source |
| DMC (Denmark) | 26 Feb 2025 | Voksne med generaliseret myastenia gravis, som er seropositive for antistoffer over for acetylcholinreceptoren (AChR Ab+… | Ikke anbefalet | source |
| ZIN (Netherlands) | 29 Aug 2024 | Advies - vergoed zilucoplan (Zilbrysq®) voor de behandeling van myasthenia gravis | reimbursed | source |
7 further decisions for zilucoplan, across 7 agencies, are not shown here. They include the most recent record on file, 3 Sep 2026 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 6 further source documents.
Related molecules
- ravulizumab — divergent outcome (recommended vs not recommended) on a shared indication
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
Coverage: 12 decisions for zilucoplan from 11 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.